

## FACSIMILE TRANSMISSION RECORD / COVER SHEET

TO

Name Examiner G. Krishnan  
Company or Firm U.S. Patent Office  
Facsimile Tel. No. 1-571-273-0654

FROM  
**PEARNE & GORDON LLP**  
1801 E. 9th Street, Suite 1200  
Cleveland, Ohio 44114-3108  
(216)579-1700

Name of Sender Paul A. Serbinowski

## COMMENTS

Date August 11, 2005 Cleveland Time 3:22 pm  
For 16 page(s), including cover sheet  
Client S&P File No. 33944

This transmission was sent from  
**(216) 579-6073**  
If you have any problem with your reception please

telephone us at (216) 579-1700 and ask for Amanda Wittine

The documents accompanying this facsimile transmission contain information from the law firm of Pearne & Gordon LLP which may be confidential or privileged. The information is intended to be for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, any disclosure, copying, distribution or use of the contents of this transmitted information is prohibited. If you have received this transmission in error, please notify us by telephone immediately so that we can arrange for the retrieval of the original documents at no cost to you.

Re: U.S. PCT-based Patent Application for  
**FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER AND MEDICAL INSTRUMENTS  
AND DRUGS BY USING THE SAME**  
Serial No.: 09/937,991  
Filed: January 23, 2002  
Atty. Docket No.: 33944

Attachments: - Amendment (13 pages) and Request for Extension of Time (2 pages).

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hirofumi Yura et al.  
Serial No.: 09/937,991  
Filing Date: January 23, 2002  
Title: "FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER AND  
MEDICAL INSTRUMENTS AND DRUGS BY USING THE SAME"  
Docket No.: S&P.33944  
Examiner: G. Krishnan

TRANSMITTED VIA FACSIMILE TO: (571) 273-0654

AMENDMENT

In response to the Office Action dated February 16, 2005, please amend the above-identified application as follows:

**(A) Introductory Comments:**

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper. Remarks begin on page 7 of this paper.